Categories: DiagnosticsNews

HTG Molecular Diagnostics to Announce Q2 2022 Financial Results and Host Conference Call on Thursday, August 11

TUCSON, Ariz., Aug. 04, 2022 (GLOBE NEWSWIRE) — HTG Molecular Diagnostics, Inc. (Nasdaq: HTGM) (HTG), a life science company advancing precision medicine through its innovative transcriptome-wide profiling technology, today announced that it will report its financial results for the quarter ended June 30, 2022 after the market close on Thursday, August 11, 2022.

Management will also host a conference call with investors to discuss financial results and provide a corporate update at 4:30pm Eastern Time. Details for the conference call are as follows:

Conference Call & Webcast Details
Date: Thursday, August 11
Time: 4:30pm ET
Toll Free: 1-800-954-0602 
International: 1-212-231-2936 
Conference ID: 22019810 
Webcast: https://viavid.webcasts.com/starthere.jsp?ei=1560944&tp_key=20e2ece390

About HTG:

HTG is accelerating precision medicine from diagnosis to treatment by harnessing the power of transcriptome-wide profiling to drive translational research, novel therapeutics and clinical diagnostics across a variety of disease areas.

Building on more than a decade of pioneering innovation and partnerships with biopharma leaders and major academic institutes, HTG’s proprietary RNA platform technologies are designed to make the development of life science tools and diagnostics more effective and efficient and to unlock a differentiated and disruptive approach to transformative drug discovery. For more information visit www.htgmolecular.com.

HTG Investor Contact:
 
Ashley Robinson
LifeSci Advisors
Phone: (617) 430-7577
Email: arr@lifesciadvisors.com

Staff

Recent Posts

KORU Medical Systems Receives FDA 510(k) Clearance for Delivery of RYSTIGGO® (rozanolixizumab-noli), Expanding Label for FreedomEDGE® Infusion System

MAHWAH, N.J.--(BUSINESS WIRE)--KORU Medical Systems, Inc. (NASDAQ: KRMD) (“KORU Medical” or the “Company”), a leading…

50 minutes ago

Hologic Announces Financial Results for First Quarter of Fiscal 2026

– Revenue of $1,047.8 Million Grows 2.5% – – GAAP Diluted EPS of $0.79 Decreases…

54 minutes ago

Illumina completes acquisition of SomaLogic

Deeply expands leadership in proteomics and multiomicsCombined capabilities bring high scalability, flexibility, and affordability into protein…

59 minutes ago

RazorMetrics Drives More Than $11 Million in Prescription Drug Savings for Ohio Plans and Residents

AUSTIN, Texas, Jan. 30, 2026 /PRNewswire/ -- RazorMetrics, a leading innovator in pharmacy cost containment…

59 minutes ago

NYSE Content Advisory: Pre-Market Update + Cast of HBO’s ‘Industry’ Rang Thursday’s Closing Bell

NEW YORK, Jan. 30, 2026 /PRNewswire/ -- The New York Stock Exchange (NYSE) provides a…

59 minutes ago

VolitionRx Limited Announces the Preparation of Reimbursement Submission for its Nu.Q® Cancer Assays

HENDERSON, Nev., Jan. 30, 2026 /PRNewswire/ -- VolitionRx Limited (NYSE AMERICAN: VNRX) ("Volition"), a multi-national…

59 minutes ago